Which treatment is better, ixazomib or bortezomib?

Ixazomib is an oral proteasome inhibitor that blocks the protein degradation process in tumor cells by inhibiting the activity of the proteasome, thereby inducing tumor cell apoptosis.

Multiple clinical trials have shown that ixazomib combined with lenalidomide and dexamethasone (IRd regimen) is effective in the treatment of multiple myeloma. For example, in the TOURMALINE-MM1 trial, the IRd regimen significantly prolonged progression-free survival (PFS).

Some side effects may occur during the use of ixazomib, such as gastrointestinal reactions, rash, bone marrow suppression, etc., but compared with the first-generation proteasome inhibitors, the incidence of peripheral neuropathy is lower.

Bortezomib is also a proteasome inhibitor, and its mechanism of action is similar to that of ixazomib. It also induces tumor cell apoptosis by inhibiting the activity of the proteasome. Bortezomib has been widely used in the treatment of multiple myeloma and is one of the first-choice treatments for multiple myeloma. It is usually used in combination with other chemotherapy drugs, such as dexamethasone, doxorubicin, etc.

Bortezomib is highly effective in the treatment of multiple myeloma, but some side effects may occur during use, such as thrombocytopenia, neurotoxicity, etc. Neurotoxicity, in particular, may limit its use in some patients.

Both ixazomib and bortezomib have shown good efficacy in the treatment of multiple myeloma. Which one is better needs to be evaluated based on the patient's specific situation. Both may have some side effects during use, but the incidence of peripheral neuropathy with ixazomib is relatively low, while the neurotoxicity of bortezomib may be more significant. Ixazomib is an oral dosage form and is relatively convenient to administer; while bortezomib usually requires intravenous injection and the administration process may be more complicated.